clinical hematology
Contributions
Type: Publication Only
Background
The geographical position of Morocco, straddling Europe and sub-Saharan Africa gives the Burkitt lymphoma equitable distribution between the endemic and the sporadic form.
Aims
The objective of this study is to evaluate the toxicity and the efficacy of LMBA02 Protocol on the Moroccan population.
Methods
This is a retrospective study including all patients managed in our training for Burkitt's lymphoma and treated using the LMBA02-Mabthera protocol.
Results
A total of 18 patients were included. The median age was 44 years, with a range of 16-70 years. The rate of men was more likely higher than women with a sex ratio [M/F] of 1.6. Diagnosis delay was 3 months average.
At diagnosis, 39% of patients had abdominal localization, 33.3% had a mandibular one, 16.6% had a neurological localization and 11% had a marrow infiltration. Two patients (11%) were infected with human immunodeficiency virus. 39% were in stage III and 39% in stage IV Murphy. 50% of patients had systemic symptoms.
All patients were treated according to the protocol LMBA02- Mabthera. The overall response rate (OR) was 83.2% with a complete response rate (CR) of 66.6% and a partial response (PR) to 16.6%. The treatment-related mortality (TRM) was 16.6%. The overall survival rate was 62% at 6 months, 50% at 1 year and 36% at 2 years; when analyzing it in terms of age, there is a 2-year survival of 75% among patients under 40 years and 14% in patients over 40 years (p <0.05). The main causes of death are dominated by treatment-related toxicity (37.5%), resistance to first-line treatment (37.5%) and relapse of the disease (25%). Both mortality risk factors are age and cure spacing due to the toxicity of treatment.
Summary
Despite its effectiveness, the treatment-related mortality of LMBA02-Mabthera protocol in patients over 40 years is considered high.
Keyword(s): Adult, Burkitt's lymphoma, Treatment
Session topic: Publication Only
Type: Publication Only
Background
The geographical position of Morocco, straddling Europe and sub-Saharan Africa gives the Burkitt lymphoma equitable distribution between the endemic and the sporadic form.
Aims
The objective of this study is to evaluate the toxicity and the efficacy of LMBA02 Protocol on the Moroccan population.
Methods
This is a retrospective study including all patients managed in our training for Burkitt's lymphoma and treated using the LMBA02-Mabthera protocol.
Results
A total of 18 patients were included. The median age was 44 years, with a range of 16-70 years. The rate of men was more likely higher than women with a sex ratio [M/F] of 1.6. Diagnosis delay was 3 months average.
At diagnosis, 39% of patients had abdominal localization, 33.3% had a mandibular one, 16.6% had a neurological localization and 11% had a marrow infiltration. Two patients (11%) were infected with human immunodeficiency virus. 39% were in stage III and 39% in stage IV Murphy. 50% of patients had systemic symptoms.
All patients were treated according to the protocol LMBA02- Mabthera. The overall response rate (OR) was 83.2% with a complete response rate (CR) of 66.6% and a partial response (PR) to 16.6%. The treatment-related mortality (TRM) was 16.6%. The overall survival rate was 62% at 6 months, 50% at 1 year and 36% at 2 years; when analyzing it in terms of age, there is a 2-year survival of 75% among patients under 40 years and 14% in patients over 40 years (p <0.05). The main causes of death are dominated by treatment-related toxicity (37.5%), resistance to first-line treatment (37.5%) and relapse of the disease (25%). Both mortality risk factors are age and cure spacing due to the toxicity of treatment.
Summary
Despite its effectiveness, the treatment-related mortality of LMBA02-Mabthera protocol in patients over 40 years is considered high.
Keyword(s): Adult, Burkitt's lymphoma, Treatment
Session topic: Publication Only